We are live on ! Find out more
BCDA icon

BioCardia

23 hedge funds and large institutions have $4.43M invested in BioCardia in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

51% more call options, than puts

Call options by funds: $539K | Put options by funds: $358K

8% more capital invested

Capital invested by funds: $4.09M → $4.43M (+$343K)

0% more funds holding

Funds holding: 2323 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0.15% less ownership

Funds ownership: 0.69%0.54% (-0.15%)

Holders
23
Holders Change
Holders Change %
0%
% of All Funds
0.36%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
7
Reduced
4
Closed
5
Calls
$539K
Puts
$358K
Net Calls
+$181K
Net Calls Change
+$582K

BCDA Hedge Fund Activity: Q2 2023 in Review

23 of the 6,382 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q2 2023, worth a combined $4.43M — up 8.4% from $4.09M a quarter earlier.

Fund positioning in BCDA was balanced in Q2 2023: 5 funds opened new positions, 5 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was Lynwood Capital Management, opening a new position worth an estimated $265K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $994K sold.

  • 23 institutional investors held BioCardia (BCDA) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $4.43M of BioCardia stock for Q2 2023, up 8.4% quarter-over-quarter.
  • 5 funds opened new BioCardia positions in Q2 2023 and 5 closed out, a net change of 0 holders.
  • The largest BioCardia buyer in Q2 2023 was Lynwood Capital Management, an estimated $265K added.
  • The largest BioCardia seller in Q2 2023 was AIGH Capital Management, an estimated $994K sold.

Based on aggregated 13F filings for Q2 2023.